ALVIMOPAN Drug Patent Profile
✉ Email this page to a colleague
When do Alvimopan patents expire, and when can generic versions of Alvimopan launch?
Alvimopan is a drug marketed by Endo Operations, Hikma, and Watson Labs Teva. and is included in three NDAs.
The generic ingredient in ALVIMOPAN is alvimopan. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the alvimopan profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Alvimopan
A generic version of ALVIMOPAN was approved as alvimopan by WATSON LABS TEVA on December 19th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALVIMOPAN?
- What are the global sales for ALVIMOPAN?
- What is Average Wholesale Price for ALVIMOPAN?
Summary for ALVIMOPAN
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 87 |
| Clinical Trials: | 31 |
| Patent Applications: | 810 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ALVIMOPAN |
| DailyMed Link: | ALVIMOPAN at DailyMed |
Recent Clinical Trials for ALVIMOPAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Oregon Health and Science University | Phase 4 |
| CMC Ambroise Paré | Phase 3 |
| Scott Steele | Phase 4 |
Pharmacology for ALVIMOPAN
| Drug Class | Opioid Antagonist |
| Mechanism of Action | Opioid Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for ALVIMOPAN
US Patents and Regulatory Information for ALVIMOPAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Operations | ALVIMOPAN | alvimopan | CAPSULE;ORAL | 216843-001 | Jan 24, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hikma | ALVIMOPAN | alvimopan | CAPSULE;ORAL | 217753-001 | Aug 31, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Watson Labs Teva | ALVIMOPAN | alvimopan | CAPSULE;ORAL | 208295-001 | Dec 19, 2019 | AB | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
